NeuroOne Medical Technologies Earnings Call Transcripts
Fiscal Year 2026
-
A novel thin film electrode platform is driving growth in neurological device markets, with strong clinical outcomes, expanding partnerships, and a robust financial outlook. Key catalysts include new product launches, international expansion, and potential partnership deals in 2026.
-
Four FDA-cleared devices target large neurological and pain markets, with strong partnerships and a unique thin-film platform driving growth. Fiscal 2026 revenue is guided at $10.5 million, with catalysts including new product launches, international expansion, and potential partnerships.
-
Q1 2026 revenue rose sequentially but was down year-over-year due to a prior large stocking order. Guidance for fiscal 2026 targets at least $10.5 million in sales, a 17% increase, with strong adoption of new products and ongoing strategic partnership discussions.
Fiscal Year 2025
-
Record product sales and improved margins drove a turnaround, with Q4 revenue up 907% year-over-year and net loss reduced by 71% for the year. FDA clearances, new product launches, and expanded partnerships position the company for continued growth in 2026.
-
Achieved $9.1M in product revenue and $3M in license revenue, expanded key partnerships, and advanced FDA-cleared products for epilepsy and pain management. Strong financial position supports growth, with new launches and strategic collaborations planned.
-
A next-generation electrode platform enables less invasive, combined diagnostic and therapeutic procedures for neurological disorders, supported by FDA-cleared products and strategic partnerships. Strong financials, expanding markets, and ongoing innovation position the company for significant growth and reduced investment risk.
-
Q3 FY2025 saw 105% product revenue growth, improved gross margins, and a narrowed net loss, driven by strong OneRF Ablation System performance and new product development. Guidance for FY2025 was reiterated, with funding secured through at least FY2026.
-
Product revenue nearly doubled year-over-year to $4.7M in the first half, with gross margins more than doubling. Guidance for FY25 is $8–$10M in product revenue, driven by Zimmer Biomet, and the company is fully funded through FY26 after a successful capital raise.
-
Record Q1 revenue and gross margin were driven by expanded Zimmer Biomet partnership and strong OneRF system adoption. FY2025 guidance is reiterated, with significant growth expected and new product launches on track.
-
Fiscal 2025 plans focus on expanding the OneRF ablation system, with strong early results and a full Zimmer Biomet launch expected after sales force training. Revenue guidance is $8–$10 million, with no debt and additional FDA submissions planned for new indications.
Fiscal Year 2024
-
FDA clearance and a strategic Zimmer Biomet partnership drove strong revenue growth in 2024, with guidance for 132%–190% revenue growth and margin improvement in 2025. Product pipeline expansion and positive clinical outcomes support a robust outlook.
-
Q3 FY2024 saw strong revenue growth, improved margins, and reduced losses, driven by the OneRF Ablation System's limited launch and new strategic partnerships. CMS reimbursement approval and new financing position the company for further expansion and product development.